As the cell therapy industry continues to grow, it must face the challenge of creating products that are not only safe and effective, but also affordable. Currently, the prices for approved products ($0.42 million) are too high for most patients, largely because of labor costs, which account for about 50% of the cost of goods in cell therapy manufacturing.
Fully automated cell therapy manufacturing processes could significantly reduce manual intervention and human errors, supporting robust processes, improving product quality, speeding product delivery, and reducing costs. In this article, we will discuss how automated cell therapy manufacturing processes may be achieved with new bioreactor and sensor technologies.
Bioreactors are vessels that permit the careful control of parameters like pH, dissolved oxygen, and temperature to ensure that cells are optimized for cell growth. Bioreactors should culture cells at sufficiently large scales to address the need for cell therapies that can deliver 10810 cells/dose.
In 1944, de Becze and Liebmann created the first bioreactor for compressed yeast production. The first bioreactor designs were large stainless-steel tanks, the bases of which were connected to pipes that could introduce air. Subsequent designs introduced impellers that could facilitate mixing and air bubble dispersal. Eventually, designs were modified to address the requirements of the food and biopharmaceutical industries. For example, designs began to incorporate antiseptic features and real-time monitoring.
Today, various types of bioreactors with special features are commercially available. Bioreactors that are commonly utilized for cell manufacturing include rocking bed, stirred tank, packed bed, and rotating wall vessel bioreactors.
The most commonly used bioreactor for bioprocessing is the stirred tank bioreactor, which is capable of scaling to large volumes (maximum volume: 20,000 L) of cell culture. However, in the stirred tank bioreactor, cell cultures are homogenized using an impeller that turns so vigorously it can affect biological processes. For example, turbulent flows and large shear forces have been found to induce the undesirable, spontaneous differentiation of stem cells.
To minimize the effects of shear forces in bioreactors, researchers developed the rocking bed bioreactor. It uses wave-like motions to ensure low shear stress and to achieve efficient nutrient diffusion. Low shear stress, researchers have found, is crucial for maintaining high cell quality.
Another bioreactor that has similar advantages for culturing sensitive primary cell lines but typically in smaller volumes (<10 L) is the rotating wall vessel bioreactor. As the name suggests, the cells are cultured inside a vessel that is rotated to produce a free-falling state. However, this system requires a complex control system to create precise rotation speeds to induce a free-falling state for continually growing cell populations. For both rocking bed and rotating wall vessel bioreactors, scalability is a challenge.
The aforementioned bioreactors are suitable for culturing non-adherent cells such as immune cells for cancer immunotherapy, but when it comes to adherent stem cells, microcarriers are required. However, the need to completely remove dissolvable microcarriers in the later stages of bioprocessing can lead to technical challenges and regulatory difficulties. To avoid these problems, the packed bed bioreactor has been designed for scalable culture of adherent-dependent cells. For example, this kind of bioreactor has been used to culture muscle cells in synthetic meat applications.
In the packed bed bioreactor, cells are seeded on a fixed bed that consists of a hollow tube with immobilized surfaces such as scaffolds, microcarriers, or porous fibers. Fresh culture media can then continuously circulate within the system to supply oxygen and nutrients. Due to the large surface area, high-density cell culture and cost efficiency can be achieved. Culture media volumes can be smaller, and operations can be less troublesome. However, the high cell densities and difficulty in effectively introducing detachment supplements into the beds can make cell harvesting challenging.
Although the bioreactor types discussed thus far present advantages such as scalability and low shear stress, they all lack the kind of automation that can reduce labor expenses, lower contamination risks, and enhance compliance with Good Manufacturing Practices. Also lacking is automation that could leverage robotics technologies. If robotics could be integrated with modular bioreactors, it would be possible to accelerate and reduce the costs of cell manufacturing.
An example of an automated system is Miltenyi Biotecs CliniMACS Prodigy. It allows users to perform cell activation, transduction, and harvesting in a completely closed and turnkey fashion. Another example is Lonzas Cocoon, a modular cell therapy manufacturing platform. Technologies to automate bioreactors are being pursued not just by individual companies, but by industry consortia such as Autostem, a multidisciplinary mix of engineers, regenerative medicine scientists, and high-technology companies.
One of the greatest needs for cell therapy automation is in autologous manufacturing, says Gregory Russotti, PhD, chief technology officer at Century Therapeutics, a biotechnology company that develops natural killer and T-cell therapies derived from induced pluripotent stem cells. Since every patient requires his or her own batch in an autologous setting, there is no way to scale up processes to produce multiple doses for different patients in larger single batches. Better methods for scale-out are therefore required, in which parallel batches can be processed more efficiently.
One approach would be to automate the processes to reduce labor needs. Automated systems could be configured to process multiple batches at the same time, thereby improving processing efficiencies and driving down the cost of goods.
One of the challenges with designing automated systems for autologous processes is that different cell therapy developers use different processes; therefore, automated methods would need to be customized to each individual process. As the field matures, it is possible that cell therapy developers will converge on some of the process steps, potentially providing the opportunity for standardized automated systems.
Automating these platforms could help reduce the risk of contamination, adds Frank Barry, PhD, professor of cellular therapy at the National University of Ireland, Galway. There are two sources of contamination in the processing of tissue-derived cell productsthe tissue itself and the operators, Barry points out. He adds that most contamination events can be traced to operator actions, such as those involving breaches in the clean room environment. Contamination events due to operators could be reduced through the use of automated robots, which permit hands free procedures and which may be subjected to sterilization.
Automated bioreactor systems are usually designed for small-scale processes, such as the generation of immune cells for personalized cancer immunotherapies. The advantage of such systems is that the cells of individual patients can be manufactured in modular bioreactors. Small, modular, and automated bioreactors can be installed in hospitals rather than remote cell manufacturing factories. This can reduce logistical complexity due to double transportation of cells and minimize cell death due to long cryopreservation periods.
When attempting to enter the clinic, you should not overinvest in technologies or process scales that are not needed for Phase I studies, Russotti advises. Simpler systems at smaller scale will typically enable you to have your process ready for clinical studies more quickly.
However, you should be thinking ahead to what the commercial scale needs to be and have a strategy as to how you will change platforms (that is, bioreactor types) and scale-up your process so that you have a commercially viable process by the time it is needed. Taking this approach inevitably requires process changes which must be carefully planned to minimize the chance of comparability failures.
Sensors are installed in bioreactors to monitor key parameters like pH, temperature, and dissolved oxygen for quality control. One of the most common sensors utilized is the probe-based electrochemical sensor, which can be produced inexpensively and works by detecting changes in electrical potential due to chemical reactions. In general, probe-based sensors can take a wide range of measurements and deliver readings quickly. However, current sensors are typically large and invasive devices. Also, they are fragile and susceptible to electronic interference.
To minimize invasiveness and improve installation flexibility, optical chemosensor systems have been developed that can detect changes in optical properties such as photoluminescence intensity and absorption due to changes in analyte concentration. These systems comprise a light source, indicator dye, optical fiber, and a light detector. Disposable sensor patches can even be placed outside of a bioreactor to minimize the risk of contamination.
Other bioreactor sensors for quality control include spectroscopic sensors. They assess interactions involving molecular bonds and electromagnetic waves to measure key variables such as biomass and abundance of cell debris. Spectroscopic sensors are noninvasive and can measure multiple variables simultaneously with near instantaneous signal delivery. However, the measurements taken with these sensors can be compromised by scattered light. To avoid this problem, the sensors are used in glass reactors.
Unfortunately, most sensor technologies are probe based and incompatible with automated, closed-system, and single-use bioreactors. Moreover, apart from spectroscopic sensors, most sensors are designed to measure a single parameter. The use of multiple invasive sensors necessitates repeated exposure of bioreactor content to the environment, heightening contamination risk.
Multiple parameters can be monitored in real time, however, with capsule technology, which is a combination of autonomous sensor technology and wireless data transmission technology. With capsule technology, wireless sensors, or capsules, are presterilized and precalibrated before they are added to cell cultures, where they float freely. It is also possible to improve the accuracy and resolution of measurements by deploying multiple capsules within the bioreactor.
Automating the monitoring of cell processing will reduce costs, increase efficiency, and improve compliance with Good Manufacturing Practices. According to Mary Murphy, PhD, professor of regenerative medicine at the National University of Ireland, Galway, automated monitoring can allow technicians to control processes remotely. That is, a process occurring inside a facility can be controlled through computer interfaces that are located outside that facility.
Cell culture is one of the most resource-consuming steps of cell manufacturing, and it relies heavily on bioreactors for scalable cell production. Fortunately, bioreactors have come a long way since they were invented for compressed yeast fermentation. They now possess features such as rocking motion technology, which can minimize shear stresses while enhancing cell viability.
However, we can anticipate that the demand for cell-based therapeutic products will increase, and that we will need to automate cell culturing and sensing technologies. Doing so will allow us to rely less on human labor and more on robust processes that will, in turn, allow us to deliver innovative cell-based treatments to patients more quickly, safely, and affordably.
Here is the original post:
Cell Therapy Manufacturing Shifts to Automatic
- Cell Therapy Basics - February 21st, 2024
- FDA Approves Amtagvi, First Cell Therapy for Skin Cancer - BioPharm International - February 21st, 2024
- Cellenkos Approved to Proceed with CK0803 Neurotrophic T regulatory Cell therapy to Treat Second Cohort in ALS Trial - PR Newswire - February 21st, 2024
- Astellas and Kelonia enter CAR-T cell therapy collaboration worth over $800m - PMLiVE - February 21st, 2024
- Bridging Therapy With CAR T-Cell Therapy in LBCL - OncLive - February 21st, 2024
- FDA approves first cell therapy to treat aggressive forms of melanoma - NPR - February 21st, 2024
- Iovance, with approval of 'TIL' cell therapy, readies for complex launch - Yahoo Finance - February 21st, 2024
- Cancer treatment: FDA approves type of cell therapy for patients with late-stage melanoma - FOX 26 Houston - February 21st, 2024
- Pharmalittle: We're reading about weight loss drugs, a cell therapy for melanoma, and more - STAT - February 21st, 2024
- On heels of cancer cell therapy win, Peninsula biotech looks to raise $211M - San Francisco Business Times - The Business Journals - February 21st, 2024
- FDA approves cell therapy to treat melanoma - FOX 26 Houston - February 21st, 2024
- Toddler Beats Childhood Leukemia After Car T-Cell Therapy - City of Hope - February 21st, 2024
- FDA Approves First One-time Cell Therapy for a Solid Tumor - BioSpace - February 21st, 2024
- Iovance wins FDA approval for cell therapy - BioProcess Insider - BioProcess Insider - February 21st, 2024
- FDA Approves Iovance Cancer Treatment, the First Cell Therapy for a Solid Tumor - MedCity News - February 21st, 2024
- Promising target for CAR T-cell therapy leads to potent antitumor responses against cutaneous and rare melanomas - Medical Xpress - February 21st, 2024
- Reinforcing Cell Therapy with Microfluidic Cell Sorting - RegMedNet - February 21st, 2024
- Study finds interleukin-24 enhances CAR-T cell therapy's effectiveness against cancer stem cells - News-Medical.Net - February 21st, 2024
- Understanding CAR T-Cell Therapy: Balancing the Risks and Benefits - Medriva - February 21st, 2024
- Keeping Track: Iovance's Amtaqvi Approval Brings T Cell Therapy To Solid Tumors - Pink Sheet - February 21st, 2024
- Tevogen Bio Holdings Inc., a Cell Therapy Company, Announces Completion of Business Combination and is to be ... - Yahoo Finance - February 21st, 2024
- What is CAR-T cell therapy, used for cancer treatment? Experts explain - India Today - India Today - February 21st, 2024
- UPDATE: 2seventy splits once more, sending cell therapy pipeline to Regeneron in 'dramatic' change - FierceBiotech - January 31st, 2024
- Revolutionary CAR T-cell therapy shows promise in reversing age-related metabolic dysfunction - News-Medical.Net - January 31st, 2024
- BioCardia Pivots to Biomarker Strategy to Prove Heart Failure Cell Therapy Benefits - precisionmedicineonline.com - January 31st, 2024
- Sequencing With CAR T-Cell Therapy for LBCL - OncLive - January 31st, 2024
- Single-cell analysis of refractory anti-SRP necrotizing myopathy treated with anti-BCMA CAR-T cell therapy ... - pnas.org - January 31st, 2024
- Regeneron to acquire 2seventy's cell therapy pipeline - Yahoo Finance - January 31st, 2024
- Trial of cell-based therapy CK08031 finishes dosing 1st patients - ALS News Today - January 31st, 2024
- Exploring Gene and Cell Therapy Integration in Pharmacies - PharmaNewsIntel - January 31st, 2024
- HBS Alumna Fighting Cancer with a Novel Cell Therapy - MBA - hbs.edu - January 31st, 2024
- YUHS partners with KURE.AI Therapeutics for cell therapy development - KBR - January 31st, 2024
- Global CAR-T Cell Therapy Market Report 2024-2034: Accelerated Growth Fueled by Intensive R&D, Growing Medical ... - Yahoo Finance - January 31st, 2024
- Oricell Announces FDA Clearance of IND Application for OriCAR-017, a novel GPRC5D Targeted CAR-T Cell Therapy ... - PR Newswire - January 31st, 2024
- A new chapter in cell therapy: engineered B cells reach the clinic for the first time - Labiotech.eu - January 31st, 2024
- Harnessing the Dark Genome: New Approach Greatly Improves Cancer T-Cell Therapy - SciTechDaily - January 31st, 2024
- Cell therapies | Harvard Stem Cell Institute (HSCI) - November 16th, 2023
- Oncternal Therapeutics Participating in Oppenheimer & Co.’s Virtual Fireside Chat: Discussion of ROR1 CAR T Cell Therapy in Hematological... - April 15th, 2023
- Basal Cell Carcinoma Treatment - The Skin Cancer Foundation - January 4th, 2023
- Adoptive Cell Therapy - Cancer Research Institute (CRI) - December 27th, 2022
- National Medical Commission prohibits use of stem cell therapy to treat patients with autism - Hindustan Times - December 18th, 2022
- Tumor buster - where will the CAR-T cell therapy missile go? - December 18th, 2022
- Gilead lands new cell therapy for Kite in $225M Arcellx deal, providing global scale for future J&J-Legend showdown - FierceBiotech - December 10th, 2022
- Non-Small Cell Lung Cancer Treatment (PDQ)Patient Version - November 24th, 2022
- CAR-T Cell Therapy Program - Frequently asked questions - November 24th, 2022
- EdiGene Announces Completion of Last Patient Dosing in Phase I Clinical Trial of ET-01, its Investigational Gene-editing Hematopoietic Stem Cell... - November 24th, 2022
- Radiation Therapy for Non-Small Cell Lung Cancer - November 6th, 2022
- AvenCell to Present New Data from Lead Universal CAR T Cell Therapy Program at 64th American Society of Hematology Annual Meeting and Exposition -... - November 6th, 2022
- Instil Bio's stock falls 35% after disclosing the cell therapy company paused enrollment in clinical trials - MarketWatch - November 6th, 2022
- Creative Medical Technology Holdings Announces FDA Clearance of Investigational New Drug (IND) Application for AlloStem, a Novel Cell Therapy for the... - November 6th, 2022
- Photodynamic Therapy to Treat Cancer - NCI - October 29th, 2022
- Researchers at University Hospitals create a breakthrough in CAR-T cell therapy for cancer patients - News 5 Cleveland WEWS - October 29th, 2022
- Mustang Bio Announces Phase 1/2 Clinical Trial Data of MB-106, a First-in-Class CD20-targeted, Autologous CAR T Cell Therapy, to be Presented at 11th... - October 29th, 2022
- Gilead, working to improve cancer cell therapy, partners with California startup - BioPharma Dive - October 21st, 2022
- Allogene starts first pivotal trials of an 'off-the-shelf' cell therapy for cancer - BioPharma Dive - October 13th, 2022
- Vita Therapeutics Closes $31 Million Series B Financing to Develop Cell Therapies for Neuromuscular Diseases and Cancers - Business Wire - October 13th, 2022
- CAR T-cell Therapy Market Riding on the Wave of Growth and will Grow at a CAGR of 30.6% to 2031 | TMR Study - GlobeNewswire - October 13th, 2022
- Inceptor Bio and Avectas Announce Collaboration to Improve Manufacturing of CAR-T Cell Therapies for the Treatment of Solid Tumors - PR Newswire - October 13th, 2022
- Cell Therapy Technologies Market Expected to Reach US ~$12.27 Billion and CAGR 14.5% by 2030 Polaris Market Research - Digital Journal - October 13th, 2022
- Early Data on GPRC5D-Directed CAR T-Cell Therapy Open Doors for New Myeloma Treatment Strategies - Precision Oncology News - October 13th, 2022
- BREAKTHROUGH TECHNOLOGY FOR IPS-DERIVED CELL THERAPIES TURNED INTO GMP PLATFORM BY TREEFROG THERAPEUTICS & INVETECH - PR Newswire - October 13th, 2022
- Cabaletta Bio Announces CABA-201, a Newly Designed CD19-Targeting CAR T Cell Therapy Engineered to Address a Broad Range of Autoimmune Diseases -... - October 13th, 2022
- Breast cancer treatment: These targeted therapies are a ray of hope for patients - Health shots - October 13th, 2022
- Two-Year Clinical Data for DiscGenics's Progenitor Cell Therapy for Lumbar Disc Degeneration to Be Presented at NASS 2022 - PR Newswire - October 13th, 2022
- Mayo Clinic Minute: What is CAR-T cell therapy? - Finger Lakes Times - October 13th, 2022
- Gamma Biosciences and Lonza Collaborate to Co-develop Reagents for Clinical Cell Selection in the Cocoon Platform USA - English - USA - English - PR... - October 13th, 2022
- Merck and Moderna Move Forward with Personalized Cancer Vaccine - BioSpace - October 13th, 2022
- First Patient With B-NHL or CLL Treated With MB-106 in Phase 1/2 Study - Targeted Oncology - October 13th, 2022
- MaxCyte to Report Third Quarter 2022 Financial Results on November 9, 2022 - Yahoo Finance - October 13th, 2022
- Iovance Biotherapeutics Announces First Patient Dosed with PD-1 Inactivated Tumor Infiltrating Lymphocyte (TIL) Therapy - GlobeNewswire - October 13th, 2022
- Elicera Therapeutics: PhD thesis describing the iTANK-platform awarded best of the year 2021 in Sweden in the field of gene and cell therapy -... - October 13th, 2022
- Integrating CAR T-Cell Therapy Into Community Oncology Practices - Targeted Oncology - October 4th, 2022
- About CAR-T cell therapy - Mayo Clinic - October 4th, 2022
- Autologous immune-cell therapy, practiced in Japan, now helping Vinmec Hospital, treat cancer patients in Hanoi, Vietnam, after technology transfer by... - October 4th, 2022
- Oncternal Therapeutics Receives IND Clearance for ONCT-808, its autologous CAR T Product Candidate Targeting ROR1 for the Treatment of Aggressive B... - October 4th, 2022
- Regenerative Spine and Pain Institute: Treating Pain with PRP and Stem Cell Therapy - Community News - October 4th, 2022
- City of Hope To Accelerate Immunotherapy Research And Treatment Innovation with $15 Million Gift From Ted Schwartz Family - City of Hope - October 4th, 2022
- Lineage Establishes New R&D Facility in U.S. and Expands Current GMP Manufacturing Facility in Israel - Business Wire - October 4th, 2022
- Century Therapeutics Announces Appointment of Daphne Quimi and Timothy Walbert to its Board of Directors - Yahoo Finance - October 4th, 2022
- SQZ Biotechnologies Publishes Preclinical Research Demonstrating SQZ AAC Platform's Potential as an Effective Red Blood Cell-Derived Immunotherapy -... - October 4th, 2022